Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1206 vs Prolia in Postmenopausal Osteoporosis
NCT07062978Phase 3Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2025
- Primary completion
- Jan 2027
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of QL1206 in postmenopausal osteoporosis (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Percent Change From Baseline in lumbar spine (LS)-Bone Mineral Density (BMD) at 12 months. Started Jun 2025; status: recruiting.
02
Drugs
QL1206
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT07062978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07062978.